Portolano Cavallo

Life Sciences

Blog

Portolano Cavallo Life Sciences Blog
15 Oct
Personal data processing in the medical research sector: What's new in the italian artificial intelligence law
On October 10, 2025, the new Italian law on artificial intelligence entered into force.
15 Oct
Public procurement of medical devices in the EU: New restrictions on access for economic operators and devices from China
On 30 June 2025, European Commission Implementing Regulation (EU) 2025/1197 came into force, introducing restrictions on access to the EU market for medical devices for economic operators and medical devices originating in the People's Republic of China.
15 Oct
The European Accessibility Act as implemented in Italy: What’s new for online pharmacies?
From June 28, 2025, the accessibility requirements provided for under the European Accessibility Act have become applicable across the European Union to a host of products and services, with Italy having transposed the EAA through Legislative Decree 27 May 2022, n° 82.
15 Oct
Pharma-influencers under the scrutiny of the Italian Self-Regulatory Body
The Monitoring Committee, issued two injunctions against two companies operating in the pharma sector for advertising disseminated by two pharma-influencers – pharmaceutical professionals who use social media and other digital communication tools to share health-related content.
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the Life Sciences-Healthcare industry.
...
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and Venture Capital transactions.

Close
October 6, 2023
CBD products: the Administrative Court suspended until October 24 the recent Decree of the Italian Ministry of Health listing cannabidiol for oral use among narcotic drugs, due to the lack o...
October 4, 2023
The Guidelines for regulating contractual relations between universities and research institutes and private sponsors were adopted by the relevant Italian Ministries following the amendment ...
September 21, 2023
CBS products: from September 20th, compositions for oral administration of cannabidiol obtained from Cannabis sativa extracts shall be considered as narcotic drugs in Italy, as they have bee...
July 27, 2023
Payback on medical devices: Italian government announces extension of payment deadline to October 30, 2023
July 21, 2023
On July 21, 2023, the Italian Ministry of Health published new guidelines on health advertising of self-medication drugs (OTC) and non-prescription drugs (SOP), including advertising on new ...
Search by...
Search
Follow us on
Follow us on